| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250;
Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756; and
Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104
Cell-based tumor vaccines, consisting of MHC class I+ tumor cells engineered to express MHC class II molecules, stimulate tumor-specific CD4+ T cells to mediate rejection of established, poorly immunogenic tumors. Previous experiments have demonstrated that these vaccines induce immunity by functioning as APCs for endogenously synthesized, tumor-encoded Ags. However, coexpression of the MHC class II accessory molecule invariant chain (Ii), or deletion of the MHC class II cytoplasmic domain abrogates vaccine immunogenicity. Recent reports have highlighted the role of lipid microdomains in Ag presentation. To determine whether Ii expression and/or truncation of MHC class II molecules impact vaccine efficacy by altering MHC class II localization to lipid microdomains, we examined the lipid raft affinity of MHC class II molecules in mouse M12.C3 B cell lymphomas and SaI/Ak sarcoma vaccine cells. Functional MHC class II heterodimers were detected in lipid rafts of both cell types. Interestingly, expression of Ii in M12.C3 cells or SaI/Ak cells blocked the MHC class II interactions with cell surface lipid rafts. In both cell types, truncation of either the 
- or 
-chain decreased the affinity of class II molecules for lipid rafts. Simultaneous deletion of both cytoplasmic domains further reduced localization of class II molecules to lipid rafts. Collectively, these data suggest that coexpression of Ii or deletion of the cytoplasmic domains of MHC class II molecules may reduce vaccine efficacy by blocking the constitutive association of MHC class II molecules with plasma membrane lipid rafts.
This article has been cited by other articles:
|
|
 |
|
  B. P. Dolan, K. D. Gibbs Jr, and S. Ostrand-Rosenberg Dendritic Cells Cross-Dressed with Peptide MHC Class I Complexes Prime CD8+ T Cells J. Immunol., November 1, 2006; 177(9): 6018 - 6024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Dolan, K. D. Gibbs Jr., and S. Ostrand-Rosenberg Tumor-Specific CD4+ T Cells Are Activated by "Cross-Dressed" Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines J. Immunol., February 1, 2006; 176(3): 1447 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Karacsonyi, T. Bedke, N. Hinrichsen, R. Schwinzer, and R. Lindner MHC II molecules and invariant chain reside in membranes distinct from conventional lipid rafts J. Leukoc. Biol., November 1, 2005; 78(5): 1097 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Dissanayake, N. Tuera, and S. Ostrand-Rosenberg Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome J. Immunol., February 15, 2005; 174(4): 1811 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Poloso, A. Muntasell, and P. A. Roche MHC Class II Molecules Traffic into Lipid Rafts during Intracellular Transport J. Immunol., October 1, 2004; 173(7): 4539 - 4546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Karacsonyi, R. Knorr, A. Fulbier, and R. Lindner Association of Major Histocompatibility Complex II with Cholesterol- and Sphingolipid-rich Membranes Precedes Peptide Loading J. Biol. Chem., August 13, 2004; 279(33): 34818 - 34826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. El Fakhry, M. Bouillon, C. Leveille, A. Brunet, H. Khalil, J. Thibodeau, and W. Mourad Delineation of the HLA-DR Region and the Residues Involved in the Association with the Cytoskeleton J. Biol. Chem., April 30, 2004; 279(18): 18472 - 18480. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
